gN2WZW ߣ鐨qʭl q$ :}X,MjVư&0ryUŤޏh, %Et]Aխk#8>4b;KuF1dV@BgyWpZ֬>+ ̲כ#Jv@X8Gň(/EwȉPɕ]Uڌ+mkf˲-+oɫة7>v6ume\Uaʹё(NϢ؈co#е/]5eA{zG1�-/F% 2ɮ6,dיcq! F+3jZ|lZ Xo;y-RvOb_?;OTxi-!O2z롸/Mdf’,@@_OoT;o O$Ǩ64`%Y/h93m&(gJc>S:”N5kExD!Kzf1|M+’X{fu6E݌ 3>.`#Ĩ?Sӌ!c8ʴ)|}R8ѥ)Ncݥdx,iA]w0″L)f|. qN{91؜TWiEO:5`c4ȉ21ԵEH”DŽYt; mp=*a܆y’ԙ>AU?a=LypBL,sŖB”C]Ӧj悌fyn0t?)dD,>”䕙s$ s{tir’.L,3Ui՜FeZu 4Mho&1Ja퍾8u>TY%*:dMvm@R/O(xJ竔ךH 37MqXq,yJ2; G6e\p*)w9=3nӗ|d1+i3En?4jfDgh,7 3|!ew_Mv4N4+a8ņlxf{nO[e C Dw9CX&(.KdZtIhn3Ѷz8rC!`\9~EV/ءaIy EI兗ŽA 4Lc_G]-









Title Post: gN2WZW ߣ鐨qʭl q$ :}X,MjVư&0ryUŤޏh, %Et]Aխk#8>4b;KuF1dV@BgyWpZ֬>+ ̲כ#Jv@X8Gň(/EwȉPɕ]Uڌ+mkf˲-+oɫة7>v6ume\Uaʹё(NϢ؈co#е/]5eA{zG1�-/F% 2ɮ6,dיcq! F+3jZ|lZ Xo;y-RvOb_?;OTxi-!O2z롸/Mdf’,@@_OoT;o O$Ǩ64`%Y/h93m&(gJc>S:”N5kExD!Kzf1|M+’X{fu6E݌ 3>.`#Ĩ?Sӌ!c8ʴ)|}R8ѥ)Ncݥdx,iA]w0″L)f|. qN{91؜TWiEO:5`c4ȉ21ԵEH”DŽYt; mp=*a܆y’ԙ>AU?a=LypBL,sŖB”C]Ӧj悌fyn0t?)dD,>”䕙s$ s{tir’.L,3Ui՜FeZu 4Mho&1Ja퍾8u>TY%*:dMvm@R/O(xJ竔ךH 37MqXq,yJ2; G6e\p*)w9=3nӗ|d1+i3En?4jfDgh,7 3|!ew_Mv4N4+a8ņlxf{nO[e C Dw9CX&(.KdZtIhn3Ѷz8rC!`\9~EV/ءaIy EI兗ŽA 4Lc_G]-
Url Post: http://www.news.fluser.com/gn2wzw-%df%a3%e9%90%a8q%ca%adl-q-xmjvu0ryut%de%8fh-eta%d5%adk84bkuf1dvbgywpz%d6%ac-%cc%b2%d7%9bjvx8gnew%c8%89p%c9%95u%da%8cmkf%cb%b2-o%c9%ab%d8%a97v6umeua%cd%b4/
Link To Post : gN2WZW ߣ鐨qʭl q$ :}X,MjVư&0ryUŤޏh, %Et]Aխk#8>4b;KuF1dV@BgyWpZ֬>+ ̲כ#Jv@X8Gň(/EwȉPɕ]Uڌ+mkf˲-+oɫة7>v6ume\Uaʹё(NϢ؈co#е/]5eA{zG1�-/F% 2ɮ6,dיcq! F+3jZ|lZ Xo;y-RvOb_?;OTxi-!O2z롸/Mdf’,@@_OoT;o O$Ǩ64`%Y/h93m&(gJc>S:”N5kExD!Kzf1|M+’X{fu6E݌ 3>.`#Ĩ?Sӌ!c8ʴ)|}R8ѥ)Ncݥdx,iA]w0″L)f|. qN{91؜TWiEO:5`c4ȉ21ԵEH”DŽYt; mp=*a܆y’ԙ>AU?a=LypBL,sŖB”C]Ӧj悌fyn0t?)dD,>”䕙s$ s{tir’.L,3Ui՜FeZu 4Mho&1Ja퍾8u>TY%*:dMvm@R/O(xJ竔ךH 37MqXq,yJ2; G6e\p*)w9=3nӗ|d1+i3En?4jfDgh,7 3|!ew_Mv4N4+a8ņlxf{nO[e C Dw9CX&(.KdZtIhn3Ѷz8rC!`\9~EV/ءaIy EI兗ŽA 4Lc_G]-
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Jennifer Lawrence: Her Most Memorable 2013 Awards Season Moments









02/25/2013 at 10:00 AM EST







Jennifer Lawrence at the Golden Globes (left), the SAG Awards and the Academy Awards


Jordan Strauss/Invision/AP; Kevin Winter/Getty


It wasn't just Jennifer Lawrence's wins making news during 2013's awards season.

The Silver Linings Playbook star, 22, was the subject of headlines for everything from her speeches to Sunday's tumble at the 85th Annual Academy Awards.

Relive Lawrence's most memorable moments here ...

Golden Globes

Lawrence kicked off awards season with an eyebrow-raising comment in her acceptance speech. After saying, "What does it say? I beat Meryl," some people – including Lindsay Lohan, who Tweeted about it – initially thought it was a jab at Meryl Streep. Lawrence later explained the comment to David Letterman, telling him it was a quote from The First Wives Club.

"First of all, it's Meryl Streep. You can't offend Meryl Streep," she said. "And then all of the sudden I hate Meryl Streep. Is that what this turned into? I don't like Meryl Streep? As if I had my eyes on getting that girl forever and I was like, 'Finally! I knew it would happen one day!' "

SAG Awards

Lawrence's Dior Haute Couture gown stole the show, but not just because of its beautiful style. While getting up to accept an award, the actress's "pants fell off," she later joked of what appeared to be a tear in the material. Lawrence, who showed off a lot of leg, made light of the incident on Piers Morgan.

Academy Awards

Hollywood's biggest night was memorable for Lawrence not only for walking away with the Best Actress statuette, but also for the way she received it. While getting up to accept the prestigious honor, she took a little tumble on the stairs in her Christian Dior Couture gown. After fellow nominee Hugh Jackman helped her up, she joked to the audience, "You guys are just standing up 'cause you feel bad that I fell and that's really embarrassing, but thank you."

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Wall Street edges up after Italy exit polls


NEW YORK (Reuters) - Stocks opened slightly higher on Monday after initial polls showed pro-reform center-leftists could win the Italian general election, though caution remained as defensive sectors led gains on the S&P 500.


The Dow Jones industrial average <.dji> rose 41.47 points or 0.3 percent, to 14,042.04, the S&P 500 <.spx> gained 6.81 points or 0.45 percent, to 1,522.41 and the Nasdaq Composite <.ixic> added 18.79 points or 0.59 percent, to 3,180.61.


(Editing by Kenneth Barry)



Read More..

IHT Rendezvous: Horsemeat Scandal Grows More Serious and More Bizarre

LONDON — As European governments struggle in vain to draw a line under the scandal over horsemeat being sold as beef, the affair seems only to be widening, in sometimes bizarre ways.

Two German politicians, for instance, suggested over the weekend that one practical use for tainted products, such as tens of thousands of packs of lasagna pulled from supermarket shelves because they contained horsemeat, would be to distribute them to the poor.

Page Two

Posts written by the IHT’s Page Two columnists.

The idea began with Hartwig Fischer, a lawmaker from Chancellor Angela Merkel’s Christian Democratic Union, who told the mass-circulation Bild Zeitung newspaper on Saturday that products shouldn’t just be thrown away. To prove his point, he was photographed and filmed eating one of the offending lasagna meals and declaring that he could not tell the difference from any other lasagna.

The development minister, Dirk Niebel, supported him, saying that, with hundreds of millions of starving people around the world, and people at home struggling to put food on the table, “I think we cannot throw away good food here in Germany.”

The idea did not meet with universal approval. The social affairs minister, Ursula von der Leyen, called it “absurd.” Some said transferring food without knowing the origin or nature of its ingredients could be illegal. And Andrea Nahles, general secretary of the opposition Social Democrats, called the very notion “an insult to people with low incomes.”

As I explore in my latest Letter From Europe column, the sensitivities about eating food packaged as beef but containing horsemeat are particularly acute in Britain.

But other nations are lining up to demand greater regulation of what goes into their processed food. On Monday, inspectors in the Czech Republic said they found horsemeat in the signature meatballs made in Sweden for the IKEA furniture group – not just food, but also a national emblem. The meatballs were distributed in the Czech Republic, Britain, Portugal, the Netherlands and Belgium, IKEA said, reflecting the gravity of the crisis and the likelihood that it will spread much further.

Read More..

Playstation 4 Games Warn of PS-Style Surveillance






The debut of the PlayStation 4 in New York City Wednesday (Feb. 20) was as remarkable for what it showed as for what it didn’t show: Sony unveiled a raft of beautiful, incredibly realistic new games, but not the console itself. The device, perhaps in a straight-from-the-lab rough appearance, was somewhere offstage, driving the giant projectors that broadcast previews of upcoming games around the Hammerstein Ballroom.


Out-of-site-yet-everywhere seems to be the overall metaphor of the PlayStation 4 (PS4), as Sony described it. The PS4 (which Sony plans to sell by year’s end) is not so much a machine as a network — with games delivered from the cloud, games that can follow you as you move from the PS4 to a mobile device, and the ability to post video clips of your adventures or even broadcast entire games online.






“We’re making it so your friends can look over your shoulder virtually and interact with you as you play,” said David Perry, co-founder of Gaikai, a company that Sony bought to build its cloud-gaming network.


But not only friends will be watching. Sony will. “The PlayStation network will get to know you by understanding your personal preferences and the preferences of your community and turn this knowledge into useful information that will enhance your gameplay,” Perry said.


Every important technology has good and bad uses. Some of the upcoming games that Sony showcased for the PS4 explore, perhaps unwittingly, the darker side of omnipresent, omniscient networks similar to what Sony is building.


Suckerpunch’s new game “inFAMOUS: Second Son” explores the surveillance state. “Right now, there are 4.2 million security cameras distributed all around Great Britain. That’s one camera for every 14 citizens,” said game director Nate Fox, in a dramatic introduction to the game. “It is hard to put your finger on what that sense of security is worth, but it is easy to say what it costs — our freedom.”


Like Great Britain, the PS4 will also have a vast network of cameras — not one for every 14 citizens, but one for every console owner. At the presentation, Marc Cerny, head of the PlayStation hardware platform, showed a photo of a depth-sensing stereo camera for the PS4, designed to track the new Dualshock controller as it moves.


The danger in “Second Son” is that some individuals have developed super-human powers (a la “Heroes”) that make them living weapons. They carry no traditional weapons and show no physical signs of danger — rendering all the modern surveillance tech impotent.


But what if new security technology could go beyond the physical? What if it could read people’s intentions and predict their next moves?


What if it were like the PS4?


Sony believes that PlayStation owners simply give off so much data as they interact intensively with the console, other devices and the network that it can know what its users intend to do.


“People haven’t’ changed, but now everybody’s broadcasting. And once you’ve seen it, all of it, how do you look away?”


That’s not a quote from a Sony or game-company executive. It’s from the lead character in the upcoming Ubisoft game “Watch Dogs.” It follows a vigilante character with access to all that information. As he walks through Chicago, message windows pop up, showing details about the people he passes. Marcus Rhodes, a 43-year-old Iraq War veteran, is unemployed. Sandy Higgins, a grade-school teacher, recently won a child-custody battle and has a 30 percent chance of being a crime victim. [See also: Is Your Cellphone Under Surveillance?]


In the clip, the vigilante uses the knowledge to find a woman in danger and to track her attacker in a chase through the city. But as the police then pursue him, the game shows how much data the protagonist himself is giving off.


It’s rather unlikely that the PlayStation 4 was designed to be a mass surveillance device, a Trojan Horse of a game console designed to slip spooks into the living room. Far likelier, Sony just wants the games to be more involving and better targeted for the customers, so they will buy and play more games.


“If we know enough about you to predict the next game you’ll purchase, then that game can be loaded and ready to go before you even click the button,” Marc Cerny said.


But still, the PS4 will collect a lot of information. That itself, in the right imagination, could be fodder for a good dystopian video game.


This story was provided by TechNewsDaily, a sister site to LiveScience. Follow TechNewsDaily on Twitter @TechNewsDaily, or on Facebook. Follow Sean Captain @seancaptain


Copyright 2013 LiveScience, a TechMediaNetwork company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Gaming News Headlines – Yahoo! News





Title Post: Playstation 4 Games Warn of PS-Style Surveillance
Url Post: http://www.news.fluser.com/playstation-4-games-warn-of-ps-style-surveillance/
Link To Post : Playstation 4 Games Warn of PS-Style Surveillance
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

You're Invited to PEOPLE.com's Oscars Party!









02/24/2013 at 08:40 AM EST







From left: Bradley Cooper, Oscar, Jessica Chastain


AFP/Getty; Wireimage; Splash News Online


Oscars host Seth MacFarlane isn't the only one gearing up for Hollywood's biggest night – we are too!

Be a part of the glamour and excitement Sunday starting at 6 p.m. ET/3 p.m. PT when we roll out the red carpet for our PEOPLE.com VIPs.

Here's what you can expect:
• Tune in to our live red carpet preshow for exclusive A-list interviews
• Be the first to see the gorgeous gowns – and make your own best-dressed list
• Download your own play-along ballot – and vote on your Academy Awards picks
• Tweet with our editors at #PeopleOscars, and watch the conversation on our homepage. We'll be joined by DKNY PR Girl (@dkny), model Coco Rocha (@cocorocha), the hilarious Go Fug Yourself (@fuggirls), @WhoWhatWear and blogger @Possessionista!
• Take our up-to-the-minute Oscars polls

And come back the next day for so much more ...
• See the night's best dresses from all angles with our 360º slideshow
• Come inside the most exclusive Oscars after-parties
• Relive the most memorable quotes of the show
• Get the scoop on the night's biggest shockers and funniest moments everyone is talking about

We're looking forward to a fun, fashion-filled night – see you then!

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Investors face another Washington deadline

NEW YORK (Reuters) - Investors face another Washington-imposed deadline on government spending cuts next week, but it's not generating the same level of fear as two months ago when the "fiscal cliff" loomed large.


Investors in sectors most likely to be affected by the cuts, like defense, seem untroubled that the budget talks could send stocks tumbling.


Talks on the U.S. budget crisis began again this week leading up to the March 1 deadline for the so-called sequestration when $85 billion in automatic federal spending cuts are scheduled to take effect.


"It's at this point a political hot button in Washington but a very low level investor concern," said Fred Dickson, chief market strategist at D.A. Davidson & Co. in Lake Oswego, Oregon. The fight pits President Barack Obama and fellow Democrats against congressional Republicans.


Stocks rallied in early January after a compromise temporarily avoided the fiscal cliff, and the Standard & Poor's 500 index <.spx> has risen 6.3 percent since the start of the year.


But the benchmark index lost steam this week, posting its first week of losses since the start of the year. Minutes on Wednesday from the last Federal Reserve meeting, which suggested the central bank may slow or stop its stimulus policy sooner than expected, provided the catalyst.


National elections in Italy on Sunday and Monday could also add to investor concern. Most investors expect a government headed by Pier Luigi Bersani to win and continue with reforms to tackle Italy's debt problems. However, a resurgence by former leader Silvio Berlusconi has raised doubts.


"Europe has been in the last six months less of a topic for the stock market, but the problems haven't gone away. This may bring back investor attention to that," said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.


OPTIONS BULLS TARGET GAINS


The spending cuts, if they go ahead, could hit the defense industry particularly hard.


Yet in the options market, bulls were targeting gains in Lockheed Martin Corp , the Pentagon's biggest supplier.


Calls on the stock far outpaced puts, suggesting that many investors anticipate the stock to move higher. Overall options volume on the stock was 2.8 times the daily average with 17,000 calls and 3,360 puts traded, according to options analytics firm Trade Alert.


"The upside call buying in Lockheed solidifies the idea that option investors are not pricing in a lot of downside risk in most defense stocks from the likely impact of sequestration," said Jared Woodard, a founder of research and advisory firm condoroptions.com in Forest, Virginia.


The stock ended up 0.6 percent at $88.12 on Friday.


If lawmakers fail to reach an agreement on reducing the U.S. budget deficit in the next few days, a sequester would include significant cuts in defense spending. Companies such as General Dynamics Corp and Smith & Wesson Holding Corp could be affected.


General Dynamics Corp shares rose 1.2 percent to $67.32 and Smith & Wesson added 4.6 percent to $9.18 on Friday.


EYES ON GDP DATA, APPLE


The latest data on fourth-quarter U.S. gross domestic product is expected on Thursday, and some analysts predict an upward revision following trade data that showed America's deficit shrank in December to its narrowest in nearly three years.


U.S. GDP unexpectedly contracted in the fourth quarter, according to an earlier government estimate, but analysts said there was no reason for panic, given that consumer spending and business investment picked up.


Investors will be looking for any hints of changes in the Fed's policy of monetary easing when Fed Chairman Ben Bernake speaks before congressional committees on Tuesday and Wednesday.


Shares of Apple will be watched closely next week when the company's annual stockholders' meeting is held.


On Friday, a U.S. judge handed outspoken hedge fund manager David Einhorn a victory in his battle with the iPhone maker, blocking the company from moving forward with a shareholder vote on a controversial proposal to limit the company's ability to issue preferred stock.


(Additional reporting by Doris Frankel; Editing by Kenneth Barry)



Read More..

IHT Rendezvous: As Oscars Fever Builds, Some Chinese Ask: ‘What About Our Films?’

BEIJING — As Oscar fever grows around the world with the 85th Academy Awards set to begin in Los Angeles just hours from now, excitement is building in China, even though it has no films in competition. There is also a sense of frustration here about why China’s movies aren’t nominated for the world’s biggest awards?

China sees itself as advancing in many ways, growing richer and more powerful, so its inability to come up with serious Oscars contenders rankles.

The most popular answer to the question, held by ordinary Chinese and film experts alike, is: “Too few good films. That’s the real reason in recent years Chinese films have moved further and further away from the Oscars dream,” wrote The International Herald Leader newspaper, in a story carried on the country’s popular Tencent entertainment site.

An article by The Economic Daily, carried on People’s Daily Web site, gave another interpretation: “The Oscars have never been a communal forum, the films taken seriously have only the responsibility to portray the North American world view and the lives they’re willing to see.”

As I’ve explored elsewhere, strict censorship hobbles the Chinese film industry. Directors are increasingly voicing their frustration in public, yet there’s little they can do against the directives of the state. One result of this hamstringing of talent is it’s virtually impossible to make probing films about contemporary society, which has many social tensions the government doesn’t want openly explored. Instead, filmmakers retreat to the safety of historical themes, with tales of warring dynasties commonplace.

Also, strict import rules governing overseas movies mean few may be shown here. As a person with the handle LA-YIN wrote on Sina Weibo, the microblog: “With the exception of Ang Lee’s ‘Life of Pi,’ none of the nominated films has screened in China.”

Much attention is being focused on a prediction of winners in an annual list drawn up by the actress Zhang Ziyi. Ms. Zhang starred in “Crouching Tiger, Hidden Dragon,” a hit in 2000 by the Taiwanese director Ang Lee. She is also the first Chinese star from the People’s Republic of China to be listed on the jury for the Oscars, in 2005, Xinhua, the state news agency, reported.

Many netizens are pointing out that Ms. Zhang’s list runs at an estimated 90 percent accuracy rate. So what’s she tapping?

Best Director? Mr. Lee and Steven Spielberg (“Lincoln”) are in tight competition, she writes. “Emotionally, I’m drawn to Ang Lee. Intellectually I’m drawn to Spielberg. These are the two films I’ve liked most this year.”

Best Film? “Lincoln. Whether you like the movie or not, it gives off glamor and radiance. I salute Spielberg’s youthfulness,” she wrote.

China is 16 hours ahead of Los Angeles, so watching will be tricky for people headed into a normal working day on Monday. As –Mostro- wrote on a microblog site, “It’s the Oscars today!!!!!!! But it’ll only be on tomorrow, Beijing time ….I can’t watch it,” followed by four yellow, grimacing emoticons.

Read More..